Pandemic Influenza Vaccine Clinical Trial Abstract Minimum information:

Title of Trial: Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years
Clinical Trial registration site if applicable (e.g. ClinicalTrials.gov): NCT00956202

Authors/sponsors: Dr M. Denis, Sanofi Pasteur

Study Design: Phase II, Randomized, double-blind trial

Vaccine:
Manufacturer: Sanofi Pasteur

Type (whole virus/subvirion/subunit/live/recombinant/DNA/vector): H1N1 inactivated split virion from the strain A/California/07/2009

Adjuvant: AF03 or None

Delivery system/site: Intramuscular injection

Doses (antigen and adjuvant): 3.8 µg or 7.5 µg or 15 µg per dose. Two doses at day: 0 and 21

Study population: 303 children of 3-8 years and 9-17 years

Age range: Health status: Healthy volunteers

Specific inclusion/exclusion criteria:
All subjects:
• Provision of Informed Consent Form signed by the subject's parent(s)/legal representative (and by an independent witness if required by local regulations). In addition, provision of Assent Form signed by subjects aged 8 to 12 years, and of Informed Consent Form signed by subjects ≥12 years.
• Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures

Subjects aged 12 to 17 years:
• Aged 12 to 17 years on the day of inclusion
• For a female of childbearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination.

Subjects aged 3 to 11 years:
• Aged 3 to 11 years on the day of inclusion

At Visit 05 (Month 8), for antibody persistence assessment:
• Having received two injections of the 15 µg HA vaccine (Group 1) or of the 3.8 µg HA + AF03 vaccine (Group 2)
• Addendum 1 to Informed Consent Form has been signed by the subject's parent(s)/guardian(s) (and by an independent witness if required by local regulations). In addition, provision of addendum 1 to Assent Form signed by subjects aged 6 to 11 years, and of addendum 1 to Informed Consent Form signed by subjects ≥ 12 years.

At Visit 06, for participants eligible for the Antibody persistence evaluation who will receive the 2010-2011 Northern Hemisphere (NH) seasonal Trivalent Influenza Vaccine:
Addendum 2 to Informed Consent Form has been signed by the subject and/or subject's parent(s)/guardian(s) (and by an independent witness if required by local regulations). In addition, provision of addendum 2 to Assent Form signed by subjects aged 6 to 11 years, and of addendum 2 to Informed Consent Form signed by subjects ≥ 12 years.

Exclusion Criteria:

All subjects:
• Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
• Planned participation in another clinical trial during the present trial period
• Receipt of any vaccine in the 4 weeks preceding the trial vaccinations
• Planned receipt of any vaccine prior to the Day 42 blood sample
• Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response
• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• Seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B antigen, or Hepatitis C as reported by parents/legal representative
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
• Thrombocytopenia contraindicating intramuscular (IM) vaccination as reported by parents/legal representative
• Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
• Chronic illness that in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
• Employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
• Previous participation in a trial investigating a vaccine with the swine-origin A/H1N1 influenza strain
• Confirmed infection with the swine-origin A/H1N1 influenza strain (different from the seasonal strain) in 2009
• Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment
• Receipt of any allergy shots and/or seasonal allergy medication in the 7-day period prior to enrollment (vaccination), or scheduled to receive any allergy shots and/or seasonal allergy medication in the 7-day period after enrollment (vaccination)

Subjects aged 12 to 17 years:
• Known pregnancy, or a positive urine pregnancy test
• Currently breastfeeding a child
• Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures

At Visit 05 (Month 8), for antibody persistence assessment: Subjects who received, in the context of a pandemic immunization program, another A/H1N1 pandemic influenza vaccine than the Investigational Medicinal Products.

Clinical Endpoints Assessed:
Safety assessments:

Immunogenicity assessments:

Results:

Safety:

Immunogenicity

GMTs:

GMT Ratios (post:pre):

Per cent responding (4 fold or greater rise and definition for reporting):

Per cent responders at specified tite: HI$\geq$40 in groups:

<table>
<thead>
<tr>
<th>Group</th>
<th>1 dose</th>
<th>2 doses</th>
<th>2 doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-8y</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>9-17</td>
<td>94%</td>
<td>100%</td>
<td>98%</td>
</tr>
</tbody>
</table>

(3.8µg+AF03)

(15µg no Adj)

Others assays:

Status of trial (ongoing/completed): Completed in 2009-2010